All Photos(1)

Documents

Y0000521

Nevirapine for peak identification

Name: Nevirapine for peak identification
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Nevirapine, 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2′,3′-e][1,4]diazepin-6-one

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₁₅H₁₄N₄O

CAS Number:

129618-40-2

Molecular Weight:

266.30

MDL number:

MFCD00866928

UNSPSC Code:

41116107

PubChem Substance ID:

329831002

NACRES:

NA.24

grade

pharmaceutical primary standard

API family

nevirapine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CC1=CC=NC2=C1NC(C(C=CC=N3)=C3N2C4CC4)=O

InChI

1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)

InChI key

NQDJXKOVJZTUJA-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analytical Reference Standards

Pharmacopeia & Metrological Institute Standards

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Nevirapine for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Nevirapine is an allosteric, non-nucleoside inhibitor of HIV reverse transcriptase (NNRTI). The K_i for inhibition of wild-type RT by Nevirapine is 200 nM.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.

Description

Pricing

1460725

1460736

1460747

PHR1757

Nevirapine, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1760

PHR1761

PHR1762

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Contemporary role of nevirapine in HIV treatment.

Laura O Coster et al.

AIDS reviews, 14(2), 132-144 (2012-05-26)

Nevirapine was the first nonnucleoside reverse transcriptase inhibitor that was approved for treatment of HIV infection and quickly became an important component of HAART. As experience with this drug grew, potential toxicities and significant clinical benefits became apparent. With the

[Evidence-based therapeutic drug monitoring for nevirapine].

Patrice Muret et al.

Therapie, 66(3), 187-195 (2011-08-09)

Nevirapine, a HIV non nucleosidic reverse transcriptase inhibitor, displays an inter-individual variability in its pharmacokinetics parameters, related to its hepatic metabolism. Based on literature, is the nevirapine therapeutic drug monitoring relevant? In naïve and pre-treated HIV infected patients, the probability

Safety of nevirapine in HIV-infected pregnant women initiating antiretroviral therapy at higher CD4 counts: a systematic review and meta-analysis.

Ebrahim Bera et al.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 102(11 Pt 1), 855-859 (2012-11-03)

The package insert for nevirapine (NVP) cautions use in HIV-infected women (including pregnant women) with CD4 counts ≥250 cells/µl. However, recent studies showed that the CD4 count of pregnant women receiving antiretroviral therapy (ART) was not predictive of NVP toxicity.

Is it safe to switch between efavirenz and nevirapine in the event of toxicity?

Ushma Mehta et al.

The Lancet. Infectious diseases, 7(11), 733-738 (2007-10-27)

The non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz and nevirapine are chemically distinct, but both may cause cutaneous hypersensitivity and hepatotoxicity. We reviewed the literature to assess the evidence for cross-reactivity between nevirapine and efavirenz. All papers, abstracts, or presentations, regardless

Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis.

Nathan Ford et al.

AIDS (London, England), 27(7), 1135-1143 (2013-01-10)

The risk of adverse drug events associated with nevirapine (NVP) is suggested to be greater in pregnant women. We conducted a systematic review and meta-analysis of severe adverse events in HIV-positive women who initiated NVP while pregnant. We searched six

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service